Trial Outcomes & Findings for Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors (NCT NCT04469569)

Last Updated: 2026-08-03

Results Overview

The primary outcome was the percentage of cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed a clinic visit (in-person or via telehealth) at one of the participating sites during the study year, and who had initiated the HPV vaccine series as of the final day of the study year, as measured via state vaccine registry records.

Recruitment status

COMPLETED

Study phase

Target enrollment

8120 participants

Primary outcome timeframe

The survivor must have initiated the HPV vaccine as of the final day of the study year

Results posted on

2026-08-03

Participant Flow

Patients included all cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed a clinic visit at one of the sites during at least one study year, resided in the state where the clinic is located, and had a record in the state vaccine registry were included. Providers included all healthcare providers licensed to order vaccines who were caring for cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy at one of the sites during at least one study year

Patients who continued to meet inclusion criteria were included in each study year during which they completed at least one clinic visit at a participating site. Healthcare providers who continued to meet inclusion criteria were invited to participate in each study year during which they continued to care for cancer survivors at a participating site

Participant milestones

Participant milestones
Measure	Early Intervention - Site D Sites randomized to the Early Intervention Arm (Sites D, E, F) will be assigned to the control condition in Year 1, to the HPV-PROTECT intervention in Year 2, and to the sustainability condition in Years 3 and 4	Early Intervention - Site E Sites randomized to the Early Intervention Arm (Sites D, E, F) will be assigned to the control condition in Year 1, to the HPV-PROTECT intervention in Year 2, and to the sustainability condition in Years 3 and 4	Early Intervention - Site F Sites randomized to the Early Intervention Arm (Sites D, E, F) will be assigned to the control condition in Year 1, to the HPV-PROTECT intervention in Year 2, and to the sustainability condition in Years 3 and 4	Delayed Intervention - Site A Sites randomized to the Delayed Intervention Arm (Sites A, B, C) will be assigned to the control condition in Years 1 and 2, to the HPV-PROTECT intervention in Year 3, and to the sustainability condition in Year 4	Delayed Intervention - Site B Sites randomized to the Delayed Intervention Arm (Sites A, B, C) will be assigned to the control condition in Years 1 and 2, to the HPV-PROTECT intervention in Year 3, and to the sustainability condition in Year 4	Delayed Intervention - Site C Sites randomized to the Delayed Intervention Arm (Sites A, B, C) will be assigned 24 months pre-intervention, followed by 12 months intervention, followed by 12 months sustainability.
Year 1 STARTED	358	221	88	575	478	104
Year 1 Patients	337	211	73	560	471	99
Year 1 Providers	21	10	15	15	7	5
Year 1 COMPLETED	358	221	88	575	478	104
Year 1 NOT COMPLETED	0	0	0	0	0	0
Year 2 STARTED	363	229	76	606	614	151
Year 2 Patients	343	219	66	587	606	146
Year 2 Providers	20	10	10	19	8	5
Year 2 COMPLETED	363	229	76	606	614	151
Year 2 NOT COMPLETED	0	0	0	0	0	0
Year 3 STARTED	380	249	89	620	634	177
Year 3 Patients	361	243	76	606	625	170
Year 3 Providers	19	6	13	14	9	7
Year 3 COMPLETED	380	249	89	620	634	177
Year 3 NOT COMPLETED	0	0	0	0	0	0
Year 4 STARTED	368	278	97	585	620	160
Year 4 Patients	355	273	81	571	612	154
Year 4 Providers	13	5	16	14	8	6
Year 4 COMPLETED	368	278	97	585	620	160
Year 4 NOT COMPLETED	0	0	0	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

This baseline measure represents the mean (standard deviation) age of survivors only at study entry.

Baseline characteristics by cohort

PRIMARY outcome

Timeframe: The survivor must have initiated the HPV vaccine as of the final day of the study year

Outcome measures

Outcome measures
Measure	Pre-Intervention n=3090 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed at least one clinic visit at one of the six participating sites during Study Year 1, and those at three sites randomized to Group 2 who completed at least one clinic visit during Study Year 2, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Intervention n=2029 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 2, and at sites randomized to Group 2 who completed at least one clinic visit during Study Year 3, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Sustainability n=2726 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 3, and at sites randomized to Group 1 or 2 who completed at least one clinic visit during Study Year 4, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.
HPV Vaccine Initiation Rates	52.2 Percentage	61.8 Percentage	62.2 Percentage

SECONDARY outcome

Timeframe: Qualitative interviews: Months 11-12 of the Intervention Year (i.e., Year 2 for sites D, E, F, and Year 3 for sites A, B, C); Quantitative survey: Administered to providers at end of pre-intervention, intervention, and sustainability phases of the study.

Descriptive statistics summarizing provider survey data and qualititatively coded provider interview data were integrated to evaluate the feasability, acceptability, and appropriateness of the HPV-PROTECT intervention to the pediatric oncology setting, and provider adherence (fidelity) to intervention components. Quantitative item: Change in healthcare provider practice of recommending HPV vaccine to their patients (item 13c): Percentage of participants reporting "often/always"

Outcome measures

Outcome measures
Measure	Pre-Intervention n=105 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed at least one clinic visit at one of the six participating sites during Study Year 1, and those at three sites randomized to Group 2 who completed at least one clinic visit during Study Year 2, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Intervention n=70 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 2, and at sites randomized to Group 2 who completed at least one clinic visit during Study Year 3, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Sustainability n=100 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 3, and at sites randomized to Group 1 or 2 who completed at least one clinic visit during Study Year 4, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.
Provider Perspectives Regarding Intervention Feasibility, Acceptability, Appropriateness, Fidelity	42.16 Percentage reporting "often/always" 1.4	75.38 Percentage reporting "often/always" .91	72.63 Percentage reporting "often/always" .88

SECONDARY outcome

Timeframe: Quantitative survey administered to providers at end of pre-intervention, intervention, and sustainability phases of the study.

Change in healthcare provider HPV and HPV vaccine-related knowledge, as measured quantitatively via 16 survey items, and reported as a combined mean score of proportion of items answered correctly (lowest possible mean score: 0; highest possible mean score: 1.0). A higher score indicates more HPV vaccine-related knowledge.

Outcome measures

Outcome measures
Measure	Pre-Intervention n=105 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed at least one clinic visit at one of the six participating sites during Study Year 1, and those at three sites randomized to Group 2 who completed at least one clinic visit during Study Year 2, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Intervention n=70 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 2, and at sites randomized to Group 2 who completed at least one clinic visit during Study Year 3, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Sustainability n=100 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 3, and at sites randomized to Group 1 or 2 who completed at least one clinic visit during Study Year 4, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.
Change in Provider HPV Vaccine-related Knowledge	.72 Score on a scale Standard Deviation .15	.80 Score on a scale Standard Deviation .10	.79 Score on a scale Standard Deviation .11

SECONDARY outcome

Timeframe: Quantitative survey administered to providers at end of pre-intervention, intervention, and sustainability phases of the study.

Change in HPV vaccine-related practices, as measured by the mean score +/- standard deviation of the healthcare provider survey responses to the following items: (a) "I order the HPV vaccine to be given to my patients in the pediatric oncology clinic" and (b) "I check to make sure that my patients complete the HPV vaccine series." Each of these two items were rated by the providers using a Likert scale with the lowest possible score of 1 ("Never") and the highest possible score of 5 ("Always"). Outcomes are reported as the Mean and Standard Deviation of the Likert scale score for each of these two survey items.

Outcome measures

Outcome measures
Measure	Pre-Intervention n=105 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed at least one clinic visit at one of the six participating sites during Study Year 1, and those at three sites randomized to Group 2 who completed at least one clinic visit during Study Year 2, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Intervention n=70 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 2, and at sites randomized to Group 2 who completed at least one clinic visit during Study Year 3, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Sustainability n=100 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 3, and at sites randomized to Group 1 or 2 who completed at least one clinic visit during Study Year 4, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.
Change in Provider HPV Vaccine-related Practices Mean/SD score: I order the HPV vaccine to be given to my patients in the peds oncology clinic	1.66 Score on a scale Standard Deviation 1.11	2.55 Score on a scale Standard Deviation 1.46	2.58 Score on a scale Standard Deviation 1.31
Change in Provider HPV Vaccine-related Practices Mean/SD score: I check to make sure that my patients complete the HPV vaccine series	2.31 Score on a scale Standard Deviation 1.30	3.42 Score on a scale Standard Deviation 1.04	3.28 Score on a scale Standard Deviation 0.98

OTHER_PRE_SPECIFIED outcome

Timeframe: The survivor must have completed the 3-dose HPV vaccine series as of the final day of the study year

The percentage of cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed a clinic visit (in-person or via telehealth) at one of the participating sites during the study year, and who had completed the 3-dose HPV vaccine series as of the final day of the study year, as measured via state vaccine registry records.

Outcome measures

Outcome measures
Measure	Pre-Intervention n=3090 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed at least one clinic visit at one of the six participating sites during Study Year 1, and those at three sites randomized to Group 2 who completed at least one clinic visit during Study Year 2, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Intervention n=2029 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 2, and at sites randomized to Group 2 who completed at least one clinic visit during Study Year 3, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Sustainability n=2726 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 3, and at sites randomized to Group 1 or 2 who completed at least one clinic visit during Study Year 4, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.
HPV Vaccine Series Completion Rates	6.6 Percentage	15.4 Percentage	21.2 Percentage

OTHER_PRE_SPECIFIED outcome

Timeframe: The survivor must have initiated the HPV vaccine as of the final day of the study year

Population: This outcome only applies to the Sustainability condition.

The percentage of cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed a clinic visit (in-person or via telehealth) at one of the participating sites during the study year, and who had initiated the HPV vaccine series as of the final day of the study year, as measured via state vaccine registry records. Applies only to the Sustainability condition.

Outcome measures

Outcome measures
Measure	Pre-Intervention n=2726 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed at least one clinic visit at one of the six participating sites during Study Year 1, and those at three sites randomized to Group 2 who completed at least one clinic visit during Study Year 2, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Intervention All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 2, and at sites randomized to Group 2 who completed at least one clinic visit during Study Year 3, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.	Sustainability All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 3, and at sites randomized to Group 1 or 2 who completed at least one clinic visit during Study Year 4, resided in the state where the clinic is located, and had a record in the state vaccine registry were included.
Sustainability of HPV Vaccine Initiation Rates	62.2 Percentage	—	—

Adverse Events

Pre-Intervention (Healthcare Providers)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Intervention (Healthcare Providers)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Sustainability (Healthcare Providers)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Wendy Landier, PhD, CRNP

University of Alabama at Birmingham

Phone: (205) 638-2120

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Measure	Pre-Intervention n=3195 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed at least one clinic visit at one of the six participating sites during Study Year 1, and those at three sites randomized to Group 2 who completed at least one clinic visit during Study Year 2, resided in the state where the clinic is located, and had a record in the state vaccine registry were included. All healthcare providers licensed to order vaccines and who were caring for cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy at one of the participating sites during Study Year 1, and those at sites randomized to Group 2 during Study Year 2, who had agreed to participate in the study, were included in the Pre-intervention portion of the analysis.	Intervention n=2099 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 2, and at sites randomized to Group 2 who completed at least one clinic visit during Study Year 3, resided in the state where the clinic is located, and had a record in the state vaccine registry were included. All healthcare providers licensed to order vaccines and who were caring for cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 during Study Year 2, and at sites randomized to Group 2 during Study Year 3, who had agreed to participate in the study, were included in the Intervention portion of the analysis.	Sustainability n=2826 Participants All cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 who completed at least one clinic visit during Study Year 3, and at sites randomized to Group 1 or 2 who completed at least one clinic visit during Study Year 4, resided in the state where the clinic is located, and had a record in the state vaccine registry were included. All healthcare providers licensed to order vaccines and who were caring for cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, at sites randomized to Group 1 during Study Year 3, and at sites randomized to Group 1 or 2 during Study Year 4, who had agreed to participate in the study, were included in the Sustainability portion of the analysis.	Total n=8120 Participants Total of all reporting groups
Age, Continuous	13.29 years STANDARD_DEVIATION 2.54 • n=3090 Participants • This baseline measure represents the mean (standard deviation) age of survivors only at study entry.	12.7 years STANDARD_DEVIATION 2.48 • n=2029 Participants • This baseline measure represents the mean (standard deviation) age of survivors only at study entry.	12.21 years STANDARD_DEVIATION 2.43 • n=2726 Participants • This baseline measure represents the mean (standard deviation) age of survivors only at study entry.	12.76 years STANDARD_DEVIATION 2.53 • n=7845 Participants • This baseline measure represents the mean (standard deviation) age of survivors only at study entry.
Age, Customized Less than 30 years	7 Participants n=105 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	2 Participants n=70 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	3 Participants n=100 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	12 Participants n=275 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.
Age, Customized 30-39 years	39 Participants n=105 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	30 Participants n=70 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	41 Participants n=100 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	110 Participants n=275 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.
Age, Customized 40-49 years	36 Participants n=105 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	23 Participants n=70 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	27 Participants n=100 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	86 Participants n=275 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.
Age, Customized 50-59 years	10 Participants n=105 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	8 Participants n=70 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	16 Participants n=100 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	34 Participants n=275 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.
Age, Customized 60 years and older	13 Participants n=105 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	7 Participants n=70 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	13 Participants n=100 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.	33 Participants n=275 Participants • This baseline measure represents the number providers only by categorical age (\<30 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older) at study entry.
Sex: Female, Male Female	1370 Participants n=3090 Participants • This baseline measure represents the count of survivors only by sex at study entry.	895 Participants n=2029 Participants • This baseline measure represents the count of survivors only by sex at study entry.	1227 Participants n=2726 Participants • This baseline measure represents the count of survivors only by sex at study entry.	3492 Participants n=7845 Participants • This baseline measure represents the count of survivors only by sex at study entry.
Sex: Female, Male Male	1720 Participants n=3090 Participants • This baseline measure represents the count of survivors only by sex at study entry.	1134 Participants n=2029 Participants • This baseline measure represents the count of survivors only by sex at study entry.	1499 Participants n=2726 Participants • This baseline measure represents the count of survivors only by sex at study entry.	4353 Participants n=7845 Participants • This baseline measure represents the count of survivors only by sex at study entry.
Sex/Gender, Customized Sex/Gender, Customized · Female	75 Participants n=105 Participants • This baseline measure represents the count of providers only by sex at study entry.	48 Participants n=70 Participants • This baseline measure represents the count of providers only by sex at study entry.	69 Participants n=100 Participants • This baseline measure represents the count of providers only by sex at study entry.	192 Participants n=275 Participants • This baseline measure represents the count of providers only by sex at study entry.
Sex/Gender, Customized Sex/Gender, Customized · Male	30 Participants n=105 Participants • This baseline measure represents the count of providers only by sex at study entry.	22 Participants n=70 Participants • This baseline measure represents the count of providers only by sex at study entry.	30 Participants n=100 Participants • This baseline measure represents the count of providers only by sex at study entry.	82 Participants n=275 Participants • This baseline measure represents the count of providers only by sex at study entry.
Sex/Gender, Customized Sex/Gender, Customized · Missing	0 Participants n=105 Participants • This baseline measure represents the count of providers only by sex at study entry.	0 Participants n=70 Participants • This baseline measure represents the count of providers only by sex at study entry.	1 Participants n=100 Participants • This baseline measure represents the count of providers only by sex at study entry.	1 Participants n=275 Participants • This baseline measure represents the count of providers only by sex at study entry.
Race/Ethnicity, Customized Hispanic	6 Participants n=105 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	3 Participants n=70 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	5 Participants n=100 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	14 Participants n=275 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry
Race/Ethnicity, Customized Non-Hispanic White	86 Participants n=105 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	59 Participants n=70 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	79 Participants n=100 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	224 Participants n=275 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry
Race/Ethnicity, Customized Non-Hispanic Black	1 Participants n=105 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	0 Participants n=70 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	1 Participants n=100 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	2 Participants n=275 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry
Race/Ethnicity, Customized Non-Hispanic Other	11 Participants n=105 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	6 Participants n=70 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	13 Participants n=100 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	30 Participants n=275 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry
Race/Ethnicity, Customized Missing	1 Participants n=105 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	2 Participants n=70 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	2 Participants n=100 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry	5 Participants n=275 Participants • This baseline measure represents the number of providers only by race/ethnicity (Hispanic, non-Hispanic White, non-Hispanic Black, Non-Hispanic Other, Missing) at study entry